Astera Labs, Inc. $ALAB Shares Acquired by Harbour Investments Inc.

Key Points

• Harbour Investments Inc. increased its holdings in Astera Labs shares by 207.7% during the 2nd quarter, bringing its total to 2,446 shares worth approximately $221,000.
• Astera Labs reported a significant year-over-year revenue increase of 149.5%, reaching $191.93 million in the latest quarter while beating EPS expectations.
• Insider transactions showed significant activity, with a director selling 183,000 shares valued at about $31.7 million, reflecting a 32.17% decrease in ownership.

Harbour Investments Inc. lifted its holdings in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 207.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,446 shares of the company's stock after acquiring an additional 1,651 shares during the period. Harbour Investments Inc.'s holdings in Astera Labs were worth $221,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Astera Labs during the 2nd quarter worth about $29,000. Bernard Wealth Management Corp. acquired a new position in Astera Labs during the second quarter worth approximately $36,000. Ameritas Advisory Services LLC acquired a new position in Astera Labs during the second quarter worth approximately $64,000. GAMMA Investing LLC increased its position in Astera Labs by 55.7% during the first quarter. GAMMA Investing LLC now owns 794 shares of the company's stock worth $47,000 after buying an additional 284 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in Astera Labs during the first quarter worth approximately $48,000. Institutional investors and hedge funds own 60.47% of the company's stock.

Astera Labs Trading Up 0.8%

Shares of ALAB stock opened at $157.51 on Wednesday. The business's 50 day moving average is $198.53 and its two-hundred day moving average is $129.72. Astera Labs, Inc. has a twelve month low of $47.13 and a twelve month high of $262.90. The company has a market capitalization of $26.18 billion, a P/E ratio of 281.27, a price-to-earnings-growth ratio of 3.89 and a beta of 1.43.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.11. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The company had revenue of $191.93 million for the quarter, compared to the consensus estimate of $172.46 million. During the same period last year, the business posted $0.13 EPS. The company's revenue was up 149.5% on a year-over-year basis. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, equities analysts predict that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Insider Transactions at Astera Labs

In related news, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $173.27, for a total value of $31,708,410.00. Following the sale, the director directly owned 385,863 shares in the company, valued at $66,858,482.01. The trade was a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Truett Tate sold 18,861 shares of Astera Labs stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $3,461,182.11. Following the completion of the sale, the chief financial officer owned 259,512 shares in the company, valued at approximately $47,623,047.12. This trade represents a 6.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,092,997 shares of company stock valued at $192,231,120. 12.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on the company. Barclays reaffirmed an "equal weight" rating and set a $155.00 price target on shares of Astera Labs in a research report on Monday. Citigroup lifted their price target on Astera Labs from $160.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, September 17th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Astera Labs in a research report on Wednesday, October 8th. Wall Street Zen raised Astera Labs from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Cowen started coverage on Astera Labs in a research note on Tuesday, September 30th. They issued a "hold" rating on the stock. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $162.06.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.